Can inhA mutation predict ethionamide resistance?

V Vadwai, K Ajbani, M Jose, V P Vineeth, C Nikam, M Deshmukh, A Shetty, R Soman, C Rodrigues

P D Hinduja National Hospital and Medical Research Centre, Mumbai, India.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2013 Jan

filter terms:

A tertiary care centre in Mumbai, India. To estimate the extent of association between inhA mutant isoniazid (INH) resistant strains and ethionamide (ETH) resistance. A total of 140 clinical isolates processed for INH and ETH phenotypic drug susceptibility testing, and molecularly processed with the line-probe assay (LPA) Genotype® MTBDRplus, were considered. Among the 112 phenotypically determined INH-resistant strains, 69 (61.6%) strains were ETH-resistant. An inhA promoter mutation was identified in 24 (21.4%) INH-resistant isolates, 21 (87.5%) of which were ETH-resistant (P < 0.0001). An inhA promoter mutation could be considered as a marker for the determination of ETH resistance in India, where the use of LPA is being expanded.

Citation

V Vadwai, K Ajbani, M Jose, V P Vineeth, C Nikam, M Deshmukh, A Shetty, R Soman, C Rodrigues. Can inhA mutation predict ethionamide resistance? The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 2013 Jan;17(1):129-30